Physician profile
Jetal Patel
NPI 1932197308
$2,791.04
in general payments reported to CMS, 2019-2025
23 companies · $801 in 2025
The $801 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $203 · 2021: $214 · 2022: $633 · 2023: $289 · 2024: $390 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.77 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $504.68 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $336.27 | 2022-2025 | Rocklatan, Clareon, Rhopressa |
| Notal Vision, INC. | $304.68 | 2022 | |
| Aerie Pharmaceuticals, INC. | $303.49 | 2019-2021 | |
| Abbvie INC. | $283.45 | 2023-2025 | |
| Amgen INC. | $212.01 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $167.02 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $105.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $96.42 | 2019-2023 | |
| Dompe US, INC. | $93.05 | 2024-2025 | Oxervate |
| Thea Pharma INC. | $50.60 | 2022-2025 | Iyuzeh |
| Astellas Pharma US INC | $47.36 | 2025 | Izervay |
| Allergan, INC. | $45.62 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $45.36 | 2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Kala Pharmaceuticals, INC. | $32.04 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $26.90 | 2023 | Acthar |
| Tarsus Pharmaceuticals, INC. | $26.68 | 2025 | Xdemvy |
| Glaukos Corporation | $21.36 | 2025 | Idosetr |
| Shire North American Group INC | $20.51 | 2019 | |
| Horizon Therapeutics Plc | $19.54 | 2022 | |
| Akorn Operating Company LLC | $17.14 | 2021 | |
| Oyster Point Pharma, INC. | $16.57 | 2023 | Tyrvaya |
| Sight Sciences, INC. | $14.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jetal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.